These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 20124009)
21. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases. Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524 [TBL] [Abstract][Full Text] [Related]
22. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286 [TBL] [Abstract][Full Text] [Related]
23. Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system. Foti C; Florean C; Pezzutto A; Roncaglia P; Tomasella A; Gustincich S; Brancolini C Mol Cancer Ther; 2009 Nov; 8(11):3140-50. PubMed ID: 19887551 [TBL] [Abstract][Full Text] [Related]
25. Imaging 26S proteasome activity and inhibition in living mice. Luker GD; Pica CM; Song J; Luker KE; Piwnica-Worms D Nat Med; 2003 Jul; 9(7):969-73. PubMed ID: 12819780 [TBL] [Abstract][Full Text] [Related]
26. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Jacquemont C; Taniguchi T Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210 [TBL] [Abstract][Full Text] [Related]
27. An historic perspective of proteasome inhibition. Esseltine DL; Mulligan G Semin Hematol; 2012 Jul; 49(3):196-206. PubMed ID: 22726542 [TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Berges C; Haberstock H; Fuchs D; Miltz M; Sadeghi M; Opelz G; Daniel V; Naujokat C Immunology; 2008 Jun; 124(2):234-46. PubMed ID: 18217957 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram. Lövborg H; Oberg F; Rickardson L; Gullbo J; Nygren P; Larsson R Int J Cancer; 2006 Mar; 118(6):1577-80. PubMed ID: 16206267 [TBL] [Abstract][Full Text] [Related]
30. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Kloss A; Meiners S; Ludwig A; Dahlmann B Cardiovasc Res; 2010 Jan; 85(2):367-75. PubMed ID: 19564153 [TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954 [TBL] [Abstract][Full Text] [Related]
32. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
33. [Classification and synthesis of ubiquitin-proteasome inhibitor]. Li J; Zhang DY; Wu XM Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462 [TBL] [Abstract][Full Text] [Related]
34. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Staff NP; Podratz JL; Grassner L; Bader M; Paz J; Knight AM; Loprinzi CL; Trushina E; Windebank AJ Neurotoxicology; 2013 Dec; 39():124-31. PubMed ID: 24035926 [TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942 [TBL] [Abstract][Full Text] [Related]
36. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Naujokat C; Berges C; Höh A; Wieczorek H; Fuchs D; Ovens J; Miltz M; Sadeghi M; Opelz G; Daniel V Immunology; 2007 Jan; 120(1):120-32. PubMed ID: 17083604 [TBL] [Abstract][Full Text] [Related]
37. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma. Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344 [TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Matondo M; Bousquet-Dubouch MP; Gallay N; Uttenweiler-Joseph S; Recher C; Payrastre B; Manenti S; Monsarrat B; Burlet-Schiltz O Leuk Res; 2010 Apr; 34(4):498-506. PubMed ID: 19811823 [TBL] [Abstract][Full Text] [Related]
39. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822 [TBL] [Abstract][Full Text] [Related]
40. Long term proteasome inhibition does not preferentially afflict motor neurons in organotypical spinal cord cultures. Vlug AS; Jaarsma D Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Mar; 5(1):16-21. PubMed ID: 15204019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]